Please login to the form below

Not currently logged in
Email:
Password:

LABA

This page shows the latest LABA news and features for those working in and with pharma, biotech and healthcare.

Novartis reveals full phase 3 results for Enerzair Breezhaler

Novartis reveals full phase 3 results for Enerzair Breezhaler

Earlier this week, the European Commission approved Enerzair Breezhaler as a maintenance treatment for asthma in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist (LABA) ... symptoms despite receiving a

Latest news

  • The end of pharma The end of pharma

    Looking back from the future, companies that marketed, say, insulin or LAMA/LABA drugs will seems like strange historical artefacts from another age.

  • AZ builds case for its COPD triple as it chases GSK’s Trelegy AZ builds case for its COPD triple as it chases GSK’s Trelegy

    Breztri – which combines long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid (ICS) budesonide – is playing catch-up in the market with GlaxoSmithKline’s

  • AZ prepares to file COPD triple, taking on rival GSK AZ prepares to file COPD triple, taking on rival GSK

    The KRONOS trial of PT010 – which combines long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid (ICS) budesonide – was presented at a medical congress ... triple –

  • AZ rival to GSK’s COPD drug Anoro fails head-to-head test AZ rival to GSK’s COPD drug Anoro fails head-to-head test

    The results of the AERISTO trial are a blow to AZ’s ambitions for Bevespi (glycopyrronium/formoterol fumarate) – a long-acting muscarinic agonist (LAMA)/long-acting beta agonist (LABA) combination that ... The real battleground between the two

  • AZ’s COPD triple data sets up market clash with GSK AZ’s COPD triple data sets up market clash with GSK

    AZ has reported phase III data from the KRONOS trial of its PT010 triple - combining long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid ... on LABA vilanterol,

More from news
Approximately 3 fully matching, plus 59 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics